B. Metzler seel. Sohn & Co. AG Cuts Stake in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• B. Metzler seel. Sohn & Co. AG significantly reduced its stake in Zimmer Biomet Holdings by 81.9%, selling 34,516 shares to end up with 7,616 shares valued at approximately $862,000.
• Zimmer Biomet reported earnings of $2.07 per share for its most recent quarter, exceeding analyst expectations and showing a 7.0% increase in revenue compared to the previous year.
• The company announced a quarterly dividend of $0.24 per share, reflecting an annual yield of 0.9%, with the ex-dividend date set for September 30th.

B. Metzler seel. Sohn & Co. AG trimmed its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 81.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,616 shares of the medical equipment provider's stock after selling 34,516 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Zimmer Biomet were worth $862,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZBH. Ameriprise Financial Inc. lifted its stake in shares of Zimmer Biomet by 236.0% in the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock valued at $517,039,000 after purchasing an additional 3,208,596 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock valued at $235,571,000 after purchasing an additional 1,488,918 shares during the period. Nuveen LLC purchased a new position in shares of Zimmer Biomet in the 1st quarter valued at approximately $155,891,000. Nuveen Asset Management LLC lifted its stake in shares of Zimmer Biomet by 191.8% in the 4th quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider's stock valued at $146,763,000 after purchasing an additional 913,310 shares during the period. Finally, Boston Trust Walden Corp purchased a new position in Zimmer Biomet during the 1st quarter valued at about $54,108,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

Shares of ZBH traded down $0.29 during mid-day trading on Thursday, hitting $104.75. 408,861 shares of the company traded hands, compared to its average volume of 2,007,745. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The stock has a 50-day moving average price of $97.88 and a two-hundred day moving average price of $99.58. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The stock has a market cap of $20.75 billion, a price-to-earnings ratio of 25.48, a P/E/G ratio of 2.09 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to analysts' expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet's dividend payout ratio is presently 23.36%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ZBH. Canaccord Genuity Group lowered their price target on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research report on Monday, May 12th. UBS Group lifted their price target on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a research report on Friday, August 8th. Raymond James Financial lifted their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Royal Bank Of Canada lifted their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Finally, Roth Capital reiterated a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Nine research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $111.44.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares in the company, valued at $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.70% of the stock is currently owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.